Skip to main content
Top
Published in: Drug Safety 5/2009

01-05-2009 | Review Article

Patch Testing for the Diagnosis of Anticonvulsant Hypersensitivity Syndrome

A Systematic Review

Authors: Abdelbaset A. Elzagallaai, Sandra R. Knowles, Michael J. Rieder, John R. Bend, Neil H. Shear, Dr Gideon Koren

Published in: Drug Safety | Issue 5/2009

Login to get access

Abstract

Anticonvulsant hypersensitivity syndrome (AHS), also known by the other names drug rash (reaction) with eosinophilia and systemic symptoms (DRESS) and drug-induced hypersensitivity syndrome (DIHS), is a rare and potentially fatal reaction that occurs in susceptible patients after exposure to certain drugs, including aromatic anticonvulsants. Because of its ill-defined clinical picture and resemblance to other diseases, the diagnosis of AHS is often difficult and requires a safe and reliable diagnostic test. The skin patch test has been proven to be very useful for prediction and diagnosis of some types of hypersensitivity reactions such as delayed drug eruptions to β-lactam antibacterials. However, the diagnostic value of patch testing for AHS is yet to be determined and its negative predictive values (NPVs) and positive predictive values (PPVs) are still unknown.
This systematic review attempts to evaluate the usefulness of patch tests in the diagnosis of AHS and to examine different technical aspects of patch testing that may contribute to its performance. We included studies in which aromatic anticonvulsant drugs are the likely causes of the hypersensitivity reaction.
Analysis of original publications from 1950 to August 2008 and cited in PubMed, MEDLINE and EMBASE has revealed contradictory findings, possibly due mainly to the use of unstandardized methods. Numerous factors have been suggested to affect the final result of the test, including the following: type of drug tested; concentration of drug and vehicle used; timing of the test after exposure; and the clinical picture of the reaction. The PPV of the test in optimal conditions was as high as 80–90% depending on the drug tested. On the other hand, this value is around 10–20% in many other published studies.
Although patch testing may be a useful diagnostic test for AHS, accurate determination of its sensitivity and specificity is yet to be achievable due to the lack of a gold standard test against which the performance of patch testing can be measured. Its PPV appears to be higher than its NPV, a matter that necessitates the use of other confirmatory tests in case of negative patch tests (e.g. careful systemic rechallenge). The benefit of testing appears to be maximal with certain drugs (i.e. carbamazepine and phenytoin) and for specific clinical manifestations (strong reactions). It should be performed 2–6 months after recovery from the date of the ADR for best results, with adequate vehicle control.
Literature
1.
go back to reference Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 1998; 39 Suppl. 7: S8–16PubMedCrossRef Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 1998; 39 Suppl. 7: S8–16PubMedCrossRef
2.
go back to reference World Health Organization. International drug monitoring: the role of national centres. World Health Organ Tech Rep Ser 1972; 498: 1–25 World Health Organization. International drug monitoring: the role of national centres. World Health Organ Tech Rep Ser 1972; 498: 1–25
3.
go back to reference Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. ADE Prevention Study Group. JAMA 1995 Jul; 274(1): 29–34PubMedCrossRef Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. ADE Prevention Study Group. JAMA 1995 Jul; 274(1): 29–34PubMedCrossRef
4.
go back to reference Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998 Apr; 279: 1200–5PubMedCrossRef Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998 Apr; 279: 1200–5PubMedCrossRef
5.
go back to reference Pouyanne P, Haramburu F, Imbs JL, et al. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. BMJ 2000 Apr; 320(7241): 1036PubMedCrossRef Pouyanne P, Haramburu F, Imbs JL, et al. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. BMJ 2000 Apr; 320(7241): 1036PubMedCrossRef
6.
go back to reference Miller GC, Britth HC, Valenti L. Adverse drug events in general practice patients in Australia. Med J Aust 2006 Apr; 184: 321–4PubMed Miller GC, Britth HC, Valenti L. Adverse drug events in general practice patients in Australia. Med J Aust 2006 Apr; 184: 321–4PubMed
7.
go back to reference Kvasz M, Allen IE, Gordon MJ, et al. Adverse drug reactions in hospitalized patients: a critique of a meta-analysis. Med Gen Med 2000 Apr; 2: E3CrossRef Kvasz M, Allen IE, Gordon MJ, et al. Adverse drug reactions in hospitalized patients: a critique of a meta-analysis. Med Gen Med 2000 Apr; 2: E3CrossRef
8.
9.
go back to reference Schlienger RG, Oh PI, Knowles SR, et al. Quantifying the costs of serious adverse drug reactions to antiepileptic drugs. Epilepsia 1998; 39 Suppl. 7: S27–32PubMedCrossRef Schlienger RG, Oh PI, Knowles SR, et al. Quantifying the costs of serious adverse drug reactions to antiepileptic drugs. Epilepsia 1998; 39 Suppl. 7: S27–32PubMedCrossRef
10.
go back to reference Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. Oxford: Oxford University Press, 1991: 18–45 Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. Oxford: Oxford University Press, 1991: 18–45
11.
go back to reference Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007; 47: 513–39PubMedCrossRef Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007; 47: 513–39PubMedCrossRef
12.
go back to reference Zimmerman HJ. Various forms of chemically induced liver injury and their detection by diagnostic procedures. Environ Health Perspect 1976 Jun; 15: 3–12PubMedCrossRef Zimmerman HJ. Various forms of chemically induced liver injury and their detection by diagnostic procedures. Environ Health Perspect 1976 Jun; 15: 3–12PubMedCrossRef
13.
go back to reference Coombs RRA, Gell PGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell PGH, Coombs RRA, Lachmann PJ, editors. Clinical aspects of immunology. London: Blackwell Scientific Publications, 1975: 761–81 Coombs RRA, Gell PGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell PGH, Coombs RRA, Lachmann PJ, editors. Clinical aspects of immunology. London: Blackwell Scientific Publications, 1975: 761–81
14.
go back to reference Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions: new concepts. Clin Exp Allergy 2007 Jul; 7: 989–99CrossRef Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions: new concepts. Clin Exp Allergy 2007 Jul; 7: 989–99CrossRef
15.
go back to reference Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003 Oct; 139: 683–93PubMed Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003 Oct; 139: 683–93PubMed
16.
go back to reference Descotes J, Choquet-Kastylevsky G. Gell and Coombs’s classification: is it still valid? Toxicology 2001 Feb; 158(1-2): 43–9PubMedCrossRef Descotes J, Choquet-Kastylevsky G. Gell and Coombs’s classification: is it still valid? Toxicology 2001 Feb; 158(1-2): 43–9PubMedCrossRef
18.
go back to reference Pohl LR, Satoh H, Christ DD, et al. The immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol Toxicol 1988; 28: 367–87PubMedCrossRef Pohl LR, Satoh H, Christ DD, et al. The immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol Toxicol 1988; 28: 367–87PubMedCrossRef
19.
go back to reference Chaiken BH, Goldberg BI, Segal JP. Dilantin sensitivity; report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med 1950 Jun 8; 242(23): 897–8PubMedCrossRef Chaiken BH, Goldberg BI, Segal JP. Dilantin sensitivity; report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med 1950 Jun 8; 242(23): 897–8PubMedCrossRef
20.
go back to reference Sontheimer RD, Houpt KR. DIDMOHS: a proposed consensus nomenclature for the drug-induced delayed multiorgan hypersensitivity syndrome. Arch Dermatol 1998 Jul; 134(7): 874–6PubMedCrossRef Sontheimer RD, Houpt KR. DIDMOHS: a proposed consensus nomenclature for the drug-induced delayed multiorgan hypersensitivity syndrome. Arch Dermatol 1998 Jul; 134(7): 874–6PubMedCrossRef
21.
go back to reference Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudo-lymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996 Dec; 15(4): 250–7PubMedCrossRef Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudo-lymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996 Dec; 15(4): 250–7PubMedCrossRef
22.
go back to reference Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988 Dec; 82(6): 1826–32PubMedCrossRef Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988 Dec; 82(6): 1826–32PubMedCrossRef
23.
go back to reference Brown KL, Henderson DC, Nadel S, et al. Carbamazepine hypersensitivity and the use of lymphocyte proliferation responses. Dev Med Child Neurol 1999 Apr; 41: 267–9PubMedCrossRef Brown KL, Henderson DC, Nadel S, et al. Carbamazepine hypersensitivity and the use of lymphocyte proliferation responses. Dev Med Child Neurol 1999 Apr; 41: 267–9PubMedCrossRef
24.
go back to reference Hebert AA, Ralston JP. Cutaneous reactions to anticonvulsant medications. J Clin Psychiatry 2001; 62 Suppl. 14: 22–6PubMed Hebert AA, Ralston JP. Cutaneous reactions to anticonvulsant medications. J Clin Psychiatry 2001; 62 Suppl. 14: 22–6PubMed
25.
go back to reference Bessmertny O, Pham T. Antiepileptic hypersensitivity syndrome: clinicians beware and be aware. Curr Allergy Asthma Rep 2002 Jan; 2: 34–9PubMedCrossRef Bessmertny O, Pham T. Antiepileptic hypersensitivity syndrome: clinicians beware and be aware. Curr Allergy Asthma Rep 2002 Jan; 2: 34–9PubMedCrossRef
26.
go back to reference Baba M, Karakas M, Aksungur VL, et al. The anticonvulsant hypersensitivity syndrome. J Eur Acad Dermatol Venereol 2003; 4: 399–401CrossRef Baba M, Karakas M, Aksungur VL, et al. The anticonvulsant hypersensitivity syndrome. J Eur Acad Dermatol Venereol 2003; 4: 399–401CrossRef
27.
go back to reference Naisbitt DJ. Drug hypersensitivity reactions in skin: understanding mechanisms and the development of diagnostic and predictive tests. Toxicology 2004 Jan; 194: 179–96PubMedCrossRef Naisbitt DJ. Drug hypersensitivity reactions in skin: understanding mechanisms and the development of diagnostic and predictive tests. Toxicology 2004 Jan; 194: 179–96PubMedCrossRef
28.
go back to reference Bavdekar SB, Muranjan MN, Gogtay NJ, et al. Anticonvulsant hypersensitivity syndrome: lymphocyte toxicity assay for the confirmation of diagnosis and risk assessment. Ann Pharmacother 2004 Oct; 38: 1648–50PubMedCrossRef Bavdekar SB, Muranjan MN, Gogtay NJ, et al. Anticonvulsant hypersensitivity syndrome: lymphocyte toxicity assay for the confirmation of diagnosis and risk assessment. Ann Pharmacother 2004 Oct; 38: 1648–50PubMedCrossRef
29.
go back to reference Kaminsky A, Moreno M, Diaz M, et al. Anticonvulsant hypersensitivity syndrome. Int J Dermatol 2005 Jul; 44: 594–8PubMedCrossRef Kaminsky A, Moreno M, Diaz M, et al. Anticonvulsant hypersensitivity syndrome. Int J Dermatol 2005 Jul; 44: 594–8PubMedCrossRef
30.
go back to reference Chopra S, Jabbar F, Pereira S, et al. Anticonvulsant hypersensitivity disorder. J Psych Intens Care 2006; 1: 117–20 Chopra S, Jabbar F, Pereira S, et al. Anticonvulsant hypersensitivity disorder. J Psych Intens Care 2006; 1: 117–20
31.
go back to reference Kim CW, Choi GS, Yun CH, et al. Drug hypersensitivity to previously tolerated phenytoin by carbamazepine-induced DRESS syndrome. J Korean Med Sci 2006 Aug; 21: 768–72PubMedCrossRef Kim CW, Choi GS, Yun CH, et al. Drug hypersensitivity to previously tolerated phenytoin by carbamazepine-induced DRESS syndrome. J Korean Med Sci 2006 Aug; 21: 768–72PubMedCrossRef
32.
go back to reference Korem M, Hiller N, Ackerman Z, et al. Spleen rupture secondary to anticonvulsant hypersensitivity syndrome. Eur J Intern Med 2006 Nov; 17: 517–9PubMedCrossRef Korem M, Hiller N, Ackerman Z, et al. Spleen rupture secondary to anticonvulsant hypersensitivity syndrome. Eur J Intern Med 2006 Nov; 17: 517–9PubMedCrossRef
33.
go back to reference Gaig P, Garcia-Ortega P, Baltasar M, et al. Drug neosensitization during anticonvulsant hypersensitivity syndrome. J Investig Allergol Clin Immunol 2006; 16: 321–6PubMed Gaig P, Garcia-Ortega P, Baltasar M, et al. Drug neosensitization during anticonvulsant hypersensitivity syndrome. J Investig Allergol Clin Immunol 2006; 16: 321–6PubMed
34.
go back to reference Schlienger RG, Shear NH. Antiepileptic drug hypersensitivity syndrome. Epilepsia 1998; 39 Suppl. 7: S3–7PubMedCrossRef Schlienger RG, Shear NH. Antiepileptic drug hypersensitivity syndrome. Epilepsia 1998; 39 Suppl. 7: S3–7PubMedCrossRef
35.
go back to reference Sharma VK, Vatve M, Sawhney IM, et al. Clinical spectrum of drug rashes due to antiepileptics. J Assoc Physicians India 1998 Jul; 46: 595–7PubMed Sharma VK, Vatve M, Sawhney IM, et al. Clinical spectrum of drug rashes due to antiepileptics. J Assoc Physicians India 1998 Jul; 46: 595–7PubMed
36.
go back to reference Peyriere H, Dereure O, Breton H, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2006 Aug; 155: 422–8PubMedCrossRef Peyriere H, Dereure O, Breton H, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2006 Aug; 155: 422–8PubMedCrossRef
37.
go back to reference Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007 Jul; 48(7): 1223–44PubMedCrossRef Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007 Jul; 48(7): 1223–44PubMedCrossRef
38.
go back to reference Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007 Mar; 156(3): 609–11PubMedCrossRef Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007 Mar; 156(3): 609–11PubMedCrossRef
39.
go back to reference Spielberg SP. In vitro analysis of idiosyncratic drug reactions. Clin Biochem 1986 Apr; 19: 142–4PubMedCrossRef Spielberg SP. In vitro analysis of idiosyncratic drug reactions. Clin Biochem 1986 Apr; 19: 142–4PubMedCrossRef
40.
go back to reference Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997 Aug; 49(2): 542–6PubMedCrossRef Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997 Aug; 49(2): 542–6PubMedCrossRef
41.
go back to reference Neuman MG, Shear NH, Malkiewicz IM, et al. Immuno-pathogenesis of hypersensitivity syndrome reactions to sulfonamides. Transl Res 2007 May; 149(5): 243–53PubMedCrossRef Neuman MG, Shear NH, Malkiewicz IM, et al. Immuno-pathogenesis of hypersensitivity syndrome reactions to sulfonamides. Transl Res 2007 May; 149(5): 243–53PubMedCrossRef
42.
go back to reference Hari Y, Frutig-Schnyder K, Hurni M, et al. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy 2001 Sep; 31(9): 1398–408PubMedCrossRef Hari Y, Frutig-Schnyder K, Hurni M, et al. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy 2001 Sep; 31(9): 1398–408PubMedCrossRef
43.
go back to reference Gogtay NJ, Bavdekar SB, Kshirsagar NA. Anticonvulsant hypersensitivity syndrome: a review. Expert Opin Drug Saf 2005 May; 4(3): 571–81PubMedCrossRef Gogtay NJ, Bavdekar SB, Kshirsagar NA. Anticonvulsant hypersensitivity syndrome: a review. Expert Opin Drug Saf 2005 May; 4(3): 571–81PubMedCrossRef
44.
go back to reference Krauss G. Current understanding of delayed anticonvulsant hypersensitivity reactions. Epilepsy Curr 2006; 6: 33–7PubMedCrossRef Krauss G. Current understanding of delayed anticonvulsant hypersensitivity reactions. Epilepsy Curr 2006; 6: 33–7PubMedCrossRef
45.
go back to reference Pichler WJ. Immune mechanism of drug hypersensitivity. Immunol Allergy Clin North Am 2004; 24(3): 373–97PubMedCrossRef Pichler WJ. Immune mechanism of drug hypersensitivity. Immunol Allergy Clin North Am 2004; 24(3): 373–97PubMedCrossRef
46.
go back to reference Spielberg SP, Gordon GB, Blake DA, et al. Anticonvulsant toxicity in vitro: possible role of arene oxides. J Pharmacol Exp Ther 1981 May; 217(2): 386–9PubMed Spielberg SP, Gordon GB, Blake DA, et al. Anticonvulsant toxicity in vitro: possible role of arene oxides. J Pharmacol Exp Ther 1981 May; 217(2): 386–9PubMed
47.
go back to reference Knowles SR, Uetrecht J, Shear NH. Idiosynchratic drug reactions: the reactive metabolite syndromes. Lancet 2000 Nov; 356: 1587–91PubMedCrossRef Knowles SR, Uetrecht J, Shear NH. Idiosynchratic drug reactions: the reactive metabolite syndromes. Lancet 2000 Nov; 356: 1587–91PubMedCrossRef
48.
go back to reference Shapiro LE, Shear NH. Mechanisms of drug reactions: the metabolic track. Semin Cutan Med Surg 1996 Dec; 15: 217–27PubMedCrossRef Shapiro LE, Shear NH. Mechanisms of drug reactions: the metabolic track. Semin Cutan Med Surg 1996 Dec; 15: 217–27PubMedCrossRef
49.
go back to reference Knowles SR, Shapiro LE, Shear NH. Reactive metabolites and adverse drug reactions: clinical considerations. Clin Rev Allergy Immunol 2003 Jun; 24(3): 229–38PubMedCrossRef Knowles SR, Shapiro LE, Shear NH. Reactive metabolites and adverse drug reactions: clinical considerations. Clin Rev Allergy Immunol 2003 Jun; 24(3): 229–38PubMedCrossRef
50.
go back to reference Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol 2005 May; 152(5): 968–74PubMedCrossRef Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol 2005 May; 152(5): 968–74PubMedCrossRef
51.
go back to reference Prens EP, Troost RJJ, Van Parys JAP, et al. The value of the lymphocyte proliferation assay in detection of carbamazepine allergy [abstract]. Contact Dermatitis 1990; 23(4): 292CrossRef Prens EP, Troost RJJ, Van Parys JAP, et al. The value of the lymphocyte proliferation assay in detection of carbamazepine allergy [abstract]. Contact Dermatitis 1990; 23(4): 292CrossRef
52.
go back to reference Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997 Feb; 27(2): 175–81PubMedCrossRef Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997 Feb; 27(2): 175–81PubMedCrossRef
53.
go back to reference Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004 Aug; 59(8): 809–20PubMedCrossRef Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004 Aug; 59(8): 809–20PubMedCrossRef
54.
go back to reference Romano A, Demoly P. Recent advances in the diagnosis of drug allergy. Curr Opin Allergy Clin Immunol 2007 Aug; 7(4): 299–303PubMed Romano A, Demoly P. Recent advances in the diagnosis of drug allergy. Curr Opin Allergy Clin Immunol 2007 Aug; 7(4): 299–303PubMed
55.
go back to reference Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003 Sep; 58(9): 854–63PubMedCrossRef Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003 Sep; 58(9): 854–63PubMedCrossRef
56.
go back to reference Black AP. A new diagnostic method in allergic disease. Pediatrics 1956; 17(5): 716–24PubMed Black AP. A new diagnostic method in allergic disease. Pediatrics 1956; 17(5): 716–24PubMed
57.
go back to reference Terr A. Controversial and unproven diagnostic tests for allergic and immunological diseases. In: Kemp SF, Lockey RF, editors. Diagnostic testing of allergic disease. New York: Marcel Dekker Inc., 2000: 307–20 Terr A. Controversial and unproven diagnostic tests for allergic and immunological diseases. In: Kemp SF, Lockey RF, editors. Diagnostic testing of allergic disease. New York: Marcel Dekker Inc., 2000: 307–20
58.
go back to reference Miranowski AC, Greenberger PA. Unproved methods and theories in allergy. Allergy Asthma Proc 2004 Jul–Aug; 25 (4 Suppl. 1): S61–3PubMed Miranowski AC, Greenberger PA. Unproved methods and theories in allergy. Allergy Asthma Proc 2004 Jul–Aug; 25 (4 Suppl. 1): S61–3PubMed
59.
go back to reference Barbaud A. Place of drug skin tests in investigating systematic cutaneous drug reactions. In: Pichler WJ, editor. Drug hypersensitivity. Basel: Karger, 2007: 366–79CrossRef Barbaud A. Place of drug skin tests in investigating systematic cutaneous drug reactions. In: Pichler WJ, editor. Drug hypersensitivity. Basel: Karger, 2007: 366–79CrossRef
60.
go back to reference Cohen DE, Brancaccio RR, Soter NA. Diagnostic tests for type IV or delayed hypersensitivity reactions. In: Kemp SF, Lockey RF, editors. Diagnostic testing of allergic disease. New York: Marcel Dekker Inc., 2000: 287–305 Cohen DE, Brancaccio RR, Soter NA. Diagnostic tests for type IV or delayed hypersensitivity reactions. In: Kemp SF, Lockey RF, editors. Diagnostic testing of allergic disease. New York: Marcel Dekker Inc., 2000: 287–305
61.
go back to reference Torres MJ, Blanca M, Fernandez J, et al. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy 2003 Oct; 58(10): 961–72PubMedCrossRef Torres MJ, Blanca M, Fernandez J, et al. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy 2003 Oct; 58(10): 961–72PubMedCrossRef
62.
go back to reference Lee AY, Choi J, Chey WY. Patch testing with carbamazepine and its main metabolite carbamazepine epoxide in cutaneous adverse drug reactions to carbamazepine. Contact Dermatitis 2003 Mar; 48(3): 137–9PubMedCrossRef Lee AY, Choi J, Chey WY. Patch testing with carbamazepine and its main metabolite carbamazepine epoxide in cutaneous adverse drug reactions to carbamazepine. Contact Dermatitis 2003 Mar; 48(3): 137–9PubMedCrossRef
63.
go back to reference Naisbitt DJ, Pirmohamed M, Park BK. Immunological principles of T-cell-mediated adverse drug reactions in skin. Expert Opin Drug Saf 2007 Mar; 6(2): 109–24PubMedCrossRef Naisbitt DJ, Pirmohamed M, Park BK. Immunological principles of T-cell-mediated adverse drug reactions in skin. Expert Opin Drug Saf 2007 Mar; 6(2): 109–24PubMedCrossRef
64.
go back to reference Osawa J, Naito S, Aihara M, et al. Evaluation of skin test reactions in patients with non-immediate type drug eruptions. J Dermatol 1990 Apr; 17(4): 235–9PubMed Osawa J, Naito S, Aihara M, et al. Evaluation of skin test reactions in patients with non-immediate type drug eruptions. J Dermatol 1990 Apr; 17(4): 235–9PubMed
65.
go back to reference Zakrzewska JM, Ivanyi L. In vitro lymphocyte proliferation by carbamazepine, carbamazepine-10, 11-epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity. J Allergy Clin Immunol 1988 Jul; 82(1): 110–5PubMedCrossRef Zakrzewska JM, Ivanyi L. In vitro lymphocyte proliferation by carbamazepine, carbamazepine-10, 11-epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity. J Allergy Clin Immunol 1988 Jul; 82(1): 110–5PubMedCrossRef
66.
go back to reference Duhra P, Foulds IS. Structural specificity of carbamaze-pine-induced dermatitis. Contact Dermatitis 1992 Nov; 27(5): 325–6PubMedCrossRef Duhra P, Foulds IS. Structural specificity of carbamaze-pine-induced dermatitis. Contact Dermatitis 1992 Nov; 27(5): 325–6PubMedCrossRef
67.
go back to reference Lertratanangkoon K, Horning MG. Metabolism of carbamazepine. Drug Metab Dispos 1982 Jan–Feb; 10(1): 1–10PubMed Lertratanangkoon K, Horning MG. Metabolism of carbamazepine. Drug Metab Dispos 1982 Jan–Feb; 10(1): 1–10PubMed
68.
go back to reference Pearce RE, Vakkalagadda GR, Leeder JS. Pathways of carbamazepine bioactivation in vitro: I. Characterization of human cytochromes P450 responsible for the formation of 2-and 3-hydroxylated metabolites. Drug Metab Dispos 2002 Nov; 30(11): 1170–9PubMedCrossRef Pearce RE, Vakkalagadda GR, Leeder JS. Pathways of carbamazepine bioactivation in vitro: I. Characterization of human cytochromes P450 responsible for the formation of 2-and 3-hydroxylated metabolites. Drug Metab Dispos 2002 Nov; 30(11): 1170–9PubMedCrossRef
69.
go back to reference Pearce RE, Uetrecht JP, Leeder JS. Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. Drug Metab Dispos 2005 Dec; 33(12): 1819–26PubMed Pearce RE, Uetrecht JP, Leeder JS. Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. Drug Metab Dispos 2005 Dec; 33(12): 1819–26PubMed
70.
go back to reference Galindo PA, Borja J, Gomez E, et al. Anticonvulsant drug hypersensitivity. J Investig Allergol Clin Immunol 2002; 12(4): 299–304PubMed Galindo PA, Borja J, Gomez E, et al. Anticonvulsant drug hypersensitivity. J Investig Allergol Clin Immunol 2002; 12(4): 299–304PubMed
71.
go back to reference Alanko K. Patch testing in cutaneous reactions caused by carbamazepine. Contact Dermatitis 1993; 29(5): 254–7PubMedCrossRef Alanko K. Patch testing in cutaneous reactions caused by carbamazepine. Contact Dermatitis 1993; 29(5): 254–7PubMedCrossRef
72.
go back to reference Fourie L, Breytenbach JC, Du Plessis J, et al. Percutaneous delivery of carbamazepine and selected N-alkyl and N-hydroxyalkyl analogues. Int J Pharm 2004 Jul 26; 279(1–2): 59–66PubMedCrossRef Fourie L, Breytenbach JC, Du Plessis J, et al. Percutaneous delivery of carbamazepine and selected N-alkyl and N-hydroxyalkyl analogues. Int J Pharm 2004 Jul 26; 279(1–2): 59–66PubMedCrossRef
73.
go back to reference Barbaud A, Goncalo M, Bruynzeel D, et al. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001 Dec; 45(6): 321–8PubMedCrossRef Barbaud A, Goncalo M, Bruynzeel D, et al. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001 Dec; 45(6): 321–8PubMedCrossRef
74.
go back to reference Puig L, Nadal C, Fernandez-Figueras MT, et al. Carba-mazepine-induced drug rashes: diagnostic value of patch tests depends on clinico-pathologic presentation. Contact Dermatitis 1996 Jun; 34(6): 435–7PubMedCrossRef Puig L, Nadal C, Fernandez-Figueras MT, et al. Carba-mazepine-induced drug rashes: diagnostic value of patch tests depends on clinico-pathologic presentation. Contact Dermatitis 1996 Jun; 34(6): 435–7PubMedCrossRef
75.
go back to reference Ljunggren B, Bojs G. A case of photosensitivity and contact allergy to systemic tricyclic drugs, with unusual features. Contact Dermatitis 1991 Apr; 24(4): 259–65PubMedCrossRef Ljunggren B, Bojs G. A case of photosensitivity and contact allergy to systemic tricyclic drugs, with unusual features. Contact Dermatitis 1991 Apr; 24(4): 259–65PubMedCrossRef
76.
go back to reference Terui T, Tagami H. Eczematous drug eruption from carbamazepine: coexistence of contact and photocontact sensitivity. Contact Dermatitis 1989 Apr; 20(4): 260–4PubMedCrossRef Terui T, Tagami H. Eczematous drug eruption from carbamazepine: coexistence of contact and photocontact sensitivity. Contact Dermatitis 1989 Apr; 20(4): 260–4PubMedCrossRef
77.
go back to reference Grims RH, Kranke B, Aberer W. Pitfalls in drug allergy skin testing: false-positive reactions due to (hidden) additives. Contact Dermatitis 2006 May; 54(5): 290–4PubMedCrossRef Grims RH, Kranke B, Aberer W. Pitfalls in drug allergy skin testing: false-positive reactions due to (hidden) additives. Contact Dermatitis 2006 May; 54(5): 290–4PubMedCrossRef
78.
go back to reference Bruze M, Isaksson M, Gruvberger B, et al. Recommendation of appropriate amounts of petrolatum preparation to be applied at patch testing. Contact Dermatitis 2007 May; 56(5): 281–5PubMedCrossRef Bruze M, Isaksson M, Gruvberger B, et al. Recommendation of appropriate amounts of petrolatum preparation to be applied at patch testing. Contact Dermatitis 2007 May; 56(5): 281–5PubMedCrossRef
79.
go back to reference Schiavino D, Nucera E, Buonomo A, et al. A case of type IV hypersensitivity to topiramate and carbamazepine. Contact Dermatitis 2005 Mar; 52(3): 161–2PubMedCrossRef Schiavino D, Nucera E, Buonomo A, et al. A case of type IV hypersensitivity to topiramate and carbamazepine. Contact Dermatitis 2005 Mar; 52(3): 161–2PubMedCrossRef
80.
go back to reference Lee AY, Kim MJ, Chey WY, et al. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur J Clin Pharmacol 2004 May; 60(3): 155–9PubMedCrossRef Lee AY, Kim MJ, Chey WY, et al. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur J Clin Pharmacol 2004 May; 60(3): 155–9PubMedCrossRef
81.
go back to reference Iemoli E, Vivirito MC, Coen M, et al. Anticonvulsant hypersensitivity syndrome due to carbamazepine. Allergy 1999; 54(12): 1329–30PubMedCrossRef Iemoli E, Vivirito MC, Coen M, et al. Anticonvulsant hypersensitivity syndrome due to carbamazepine. Allergy 1999; 54(12): 1329–30PubMedCrossRef
82.
go back to reference Ozkaya-Bayazit E, Gungor H. Carbamazepine induced eczematous eruption-clinically resembling atopic dermatitis. J Eur Acad Dermatol Venereol 1999 Mar; 12(2): 182–3PubMedCrossRef Ozkaya-Bayazit E, Gungor H. Carbamazepine induced eczematous eruption-clinically resembling atopic dermatitis. J Eur Acad Dermatol Venereol 1999 Mar; 12(2): 182–3PubMedCrossRef
83.
go back to reference Wolkenstein P, Chosidow O, Flechet ML, et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996 Oct; 35(4): 234–6PubMedCrossRef Wolkenstein P, Chosidow O, Flechet ML, et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996 Oct; 35(4): 234–6PubMedCrossRef
84.
go back to reference Jones M, Fernandez-Herrera J, Dorado JM, et al. Epicu-taneous test in carbamazepine cutaneous reactions. Dermatology 1994; 188(1): 18–20PubMedCrossRef Jones M, Fernandez-Herrera J, Dorado JM, et al. Epicu-taneous test in carbamazepine cutaneous reactions. Dermatology 1994; 188(1): 18–20PubMedCrossRef
85.
go back to reference Vaillant L, Camenen I, Lorette G. Patch testing with carbamazepine: reinduction of an exfoliative dermatitis [letter]. Arch Dermatol 1989; 125(2): 299PubMedCrossRef Vaillant L, Camenen I, Lorette G. Patch testing with carbamazepine: reinduction of an exfoliative dermatitis [letter]. Arch Dermatol 1989; 125(2): 299PubMedCrossRef
86.
go back to reference Silva R, Machado A, Brandao M, et al. Patch test diagnosis in carbamazepine erythroderma. Contact Dermatitis 1986; 15(4): 254–5PubMedCrossRef Silva R, Machado A, Brandao M, et al. Patch test diagnosis in carbamazepine erythroderma. Contact Dermatitis 1986; 15(4): 254–5PubMedCrossRef
87.
go back to reference Conilleau V, Dompmartin A, Verneuil L, et al. Hypersensitivity syndrome due to 2 anticonvulsant drugs. Contact Dermatitis 1999 Sep; 41(3): 141–4PubMedCrossRef Conilleau V, Dompmartin A, Verneuil L, et al. Hypersensitivity syndrome due to 2 anticonvulsant drugs. Contact Dermatitis 1999 Sep; 41(3): 141–4PubMedCrossRef
88.
go back to reference Troost RJ, Van Parys JA, Hooijkaas H, et al. Allergy to carbamazepine: parallel in vivo and in vitro detection. Epilepsia 1996 Nov; 37(11): 1093–9PubMedCrossRef Troost RJ, Van Parys JA, Hooijkaas H, et al. Allergy to carbamazepine: parallel in vivo and in vitro detection. Epilepsia 1996 Nov; 37(11): 1093–9PubMedCrossRef
89.
go back to reference Friedmann PS, Strickland I, Pirmohamed M, et al. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994 May; 30(5): 598–604CrossRef Friedmann PS, Strickland I, Pirmohamed M, et al. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994 May; 30(5): 598–604CrossRef
90.
go back to reference Romaguera C, Grimalt F, Vilaplana J, et al. Erythroderma from carbamazepine. Contact Dermatitis 1989; 20(4): 304–5PubMedCrossRef Romaguera C, Grimalt F, Vilaplana J, et al. Erythroderma from carbamazepine. Contact Dermatitis 1989; 20(4): 304–5PubMedCrossRef
91.
go back to reference Fernandez de Corres L, Leanizbarrutia I, Munoz D. Eczematous drug reaction from phenobarbitone. Contact Dermatitis 1984; 11(5): 319CrossRef Fernandez de Corres L, Leanizbarrutia I, Munoz D. Eczematous drug reaction from phenobarbitone. Contact Dermatitis 1984; 11(5): 319CrossRef
92.
go back to reference Ulrich G, Schmutz JL, Trechot P, et al. Sensitization to petrolatum: an unusual cause of false-positive drug patch-tests. Allergy 2004 Sep; 59(9): 1006–9PubMedCrossRef Ulrich G, Schmutz JL, Trechot P, et al. Sensitization to petrolatum: an unusual cause of false-positive drug patch-tests. Allergy 2004 Sep; 59(9): 1006–9PubMedCrossRef
93.
go back to reference Gammelgaard B, Fullerton A, Avnstorp C, et al. In vitro evaluation of water and petrolatum as vehicles in chro-mate patch testing. Contact Dermatitis 1992 Nov; 27(5): 317–8PubMedCrossRef Gammelgaard B, Fullerton A, Avnstorp C, et al. In vitro evaluation of water and petrolatum as vehicles in chro-mate patch testing. Contact Dermatitis 1992 Nov; 27(5): 317–8PubMedCrossRef
94.
go back to reference Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 2004; 209(2): 209–16CrossRef Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 2004; 209(2): 209–16CrossRef
95.
go back to reference Scerri L, Shall L, Zaki I. Carbamazepine-induced anticonvulsant hypersensitivity syndrome: pathogenic and diagnostic considerations. Clin Exp Dermatol 1993; 18(6): 540–2PubMedCrossRef Scerri L, Shall L, Zaki I. Carbamazepine-induced anticonvulsant hypersensitivity syndrome: pathogenic and diagnostic considerations. Clin Exp Dermatol 1993; 18(6): 540–2PubMedCrossRef
96.
go back to reference Houwerzijl J, De Gast GC, Nater JP, et al. Lymphocyte-stimulation tests and patch tests to carbamazepine hypersensitivity. Clin Exp Immunol 1977; 29(2): 272–7PubMed Houwerzijl J, De Gast GC, Nater JP, et al. Lymphocyte-stimulation tests and patch tests to carbamazepine hypersensitivity. Clin Exp Immunol 1977; 29(2): 272–7PubMed
97.
go back to reference Beeler A, Engler O, Gerber BO, et al. Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. J Allergy Clin Immunol 2006 Feb; 117(2): 455–62PubMedCrossRef Beeler A, Engler O, Gerber BO, et al. Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. J Allergy Clin Immunol 2006 Feb; 117(2): 455–62PubMedCrossRef
98.
go back to reference Monzon S, Garces MM, Reichelt C, et al. Positive patch test in hypersensitivity to lamotrigine. Contact Dermatitis 2002; 47(6): 361PubMedCrossRef Monzon S, Garces MM, Reichelt C, et al. Positive patch test in hypersensitivity to lamotrigine. Contact Dermatitis 2002; 47(6): 361PubMedCrossRef
99.
go back to reference Troost RJ, Oranje AP, Lijnen RL, et al. Exfoliative dermatitis due to immunologically confirmed carbamazepine hypersensitivity. Pediatr Dermatol 1996 Jul–Aug; 13(4): 316–20PubMedCrossRef Troost RJ, Oranje AP, Lijnen RL, et al. Exfoliative dermatitis due to immunologically confirmed carbamazepine hypersensitivity. Pediatr Dermatol 1996 Jul–Aug; 13(4): 316–20PubMedCrossRef
100.
go back to reference Yasuda S, Mizuno N, Kawabe Y, et al. Photosensitive lichenoid reaction accompanied by nonphotosensitive subacute prurigo caused by carbamazepine. Photo-dermatol 1988; 5(5): 206–10 Yasuda S, Mizuno N, Kawabe Y, et al. Photosensitive lichenoid reaction accompanied by nonphotosensitive subacute prurigo caused by carbamazepine. Photo-dermatol 1988; 5(5): 206–10
101.
go back to reference Okuyama R, Ichinohasama R, Tagami H. Carbamazepine induced erythroderma with systemic lymphadenopathy. J Dermatol 1996; 23(7): 489–94PubMed Okuyama R, Ichinohasama R, Tagami H. Carbamazepine induced erythroderma with systemic lymphadenopathy. J Dermatol 1996; 23(7): 489–94PubMed
102.
go back to reference Alanko K, Stubb S, Kauppinen K. Cutaneous drug reactions: clinical types and causative agents. A five-year survey of in-patients (1981–1985). Acta Derm Venereol 1989; 69(3): 223–6PubMed Alanko K, Stubb S, Kauppinen K. Cutaneous drug reactions: clinical types and causative agents. A five-year survey of in-patients (1981–1985). Acta Derm Venereol 1989; 69(3): 223–6PubMed
103.
go back to reference Pelekanos J, Camfield P, Camfield C, et al. Allergic rash due to antiepileptic drugs: clinical features and management. Epilepsia 1991 Jul–Aug; 32(4): 554–9PubMedCrossRef Pelekanos J, Camfield P, Camfield C, et al. Allergic rash due to antiepileptic drugs: clinical features and management. Epilepsia 1991 Jul–Aug; 32(4): 554–9PubMedCrossRef
104.
go back to reference Alanko K, Stubb S, Reitamo S. Topical provocation of fixed drug eruption. Br J Dermatol 1987 Apr; 116(4): 561–7PubMedCrossRef Alanko K, Stubb S, Reitamo S. Topical provocation of fixed drug eruption. Br J Dermatol 1987 Apr; 116(4): 561–7PubMedCrossRef
105.
go back to reference Perez-Ezquerra PR, de Barrio Fernandez M, de Castro Martinez FJ, et al. Delayed hypersensitivity to hydroxychloroquine manifested by two different types of cutaneous eruptions in the same patient. Allergol Immunopathol (Madr) 2006 Jul–Aug; 34(4): 174–5CrossRef Perez-Ezquerra PR, de Barrio Fernandez M, de Castro Martinez FJ, et al. Delayed hypersensitivity to hydroxychloroquine manifested by two different types of cutaneous eruptions in the same patient. Allergol Immunopathol (Madr) 2006 Jul–Aug; 34(4): 174–5CrossRef
106.
go back to reference Manning ME, Stevenson DD. Pseudo-allergic drug reaction: aspirin, nonsteroidal antiinflamatory drugs, dyes, additives and preservatives. Immunol Allergy Clin N Am 1991; 11(3): 659–78 Manning ME, Stevenson DD. Pseudo-allergic drug reaction: aspirin, nonsteroidal antiinflamatory drugs, dyes, additives and preservatives. Immunol Allergy Clin N Am 1991; 11(3): 659–78
107.
go back to reference De Weck AL. Immunopathological mechanisms and clinical aspects of allergic reactions. In: De Weck AL, Bundgaard H, editors. Allergic reactions to drugs. New York: Springer-Verlag, 1983: 75–133CrossRef De Weck AL. Immunopathological mechanisms and clinical aspects of allergic reactions. In: De Weck AL, Bundgaard H, editors. Allergic reactions to drugs. New York: Springer-Verlag, 1983: 75–133CrossRef
108.
go back to reference Goh CL. Prevalence of contact allergy by sex, race and age. Contact Dermatitis 1986 Apr; 14(4): 237–40PubMedCrossRef Goh CL. Prevalence of contact allergy by sex, race and age. Contact Dermatitis 1986 Apr; 14(4): 237–40PubMedCrossRef
109.
go back to reference Modjtahedi SP, Maibach HI. Ethnicity as a possible endogenous factor in irritant contact dermatitis: comparing the irritant response among Caucasians, blacks, and Asians. Contact Dermatitis 2002 Nov; 47(5): 272–8PubMedCrossRef Modjtahedi SP, Maibach HI. Ethnicity as a possible endogenous factor in irritant contact dermatitis: comparing the irritant response among Caucasians, blacks, and Asians. Contact Dermatitis 2002 Nov; 47(5): 272–8PubMedCrossRef
110.
go back to reference Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach: I. Blood flow, pH, thickness, and ultrasound echogenicity. Skin Res Technol 2005 Nov; 11(4): 221–35PubMedCrossRef Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach: I. Blood flow, pH, thickness, and ultrasound echogenicity. Skin Res Technol 2005 Nov; 11(4): 221–35PubMedCrossRef
111.
go back to reference Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach: II. Protein, glycosa-minoglycan, water, and lipid content and structure. Skin Res Technol 2006 Aug; 12(3): 145–54PubMedCrossRef Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach: II. Protein, glycosa-minoglycan, water, and lipid content and structure. Skin Res Technol 2006 Aug; 12(3): 145–54PubMedCrossRef
112.
go back to reference Modjtahedi BS, Modjtahedi SP, Maibach HI. The sex of the individual as a factor in allergic contact dermatitis. Contact Dermatitis 2004 Feb; 50(2): 53–9PubMedCrossRef Modjtahedi BS, Modjtahedi SP, Maibach HI. The sex of the individual as a factor in allergic contact dermatitis. Contact Dermatitis 2004 Feb; 50(2): 53–9PubMedCrossRef
113.
go back to reference Wohrl S, Hemmer W, Focke M, et al. Patch testing in children, adults, and the elderly: influence of age and sex on sensitization patterns. Pediatr Dermatol 2003 Mar–Apr; 20(2): 119–23PubMedCrossRef Wohrl S, Hemmer W, Focke M, et al. Patch testing in children, adults, and the elderly: influence of age and sex on sensitization patterns. Pediatr Dermatol 2003 Mar–Apr; 20(2): 119–23PubMedCrossRef
114.
go back to reference Sánchez-Morillas L, Laguna-Martínez JJ, Reaño-Martos M, et al. A case of hypersensitivity syndrome due to phenytoin. J Investig Allergol Clin Immunol 2008; 18(1): 74–5PubMed Sánchez-Morillas L, Laguna-Martínez JJ, Reaño-Martos M, et al. A case of hypersensitivity syndrome due to phenytoin. J Investig Allergol Clin Immunol 2008; 18(1): 74–5PubMed
115.
go back to reference Balatsinou C, Milano A, Caldarella MP, et al. Eosinophilic esophagitis is a component of the anticonvulsant hypersensitivity syndrome: description of two cases. Dig Liver Dis 2008 Feb; 40(2): 145–8PubMedCrossRef Balatsinou C, Milano A, Caldarella MP, et al. Eosinophilic esophagitis is a component of the anticonvulsant hypersensitivity syndrome: description of two cases. Dig Liver Dis 2008 Feb; 40(2): 145–8PubMedCrossRef
116.
go back to reference Romano A, Pettinato R, Andriolo M, et al. Hypersensitivity to aromatic anticonvulsants: in vivo and in vitro cross-reactivity studies. Curr Pharm Des 2006; 12(26): 3373–81PubMedCrossRef Romano A, Pettinato R, Andriolo M, et al. Hypersensitivity to aromatic anticonvulsants: in vivo and in vitro cross-reactivity studies. Curr Pharm Des 2006; 12(26): 3373–81PubMedCrossRef
117.
go back to reference Hara H, Kobayashi M, Yokoyama A, et al. Drug-induced hypersensitivity syndrome due to carbamazepine associated with reactivation of human herpesvirus 7. Dermatology 2005; 211(2): 159–61PubMedCrossRef Hara H, Kobayashi M, Yokoyama A, et al. Drug-induced hypersensitivity syndrome due to carbamazepine associated with reactivation of human herpesvirus 7. Dermatology 2005; 211(2): 159–61PubMedCrossRef
118.
119.
go back to reference Gex-Collet C, Helbling A, Pichler WJ. Multiple drug hypersensitivity: proof of multiple drug hypersensitivity by patch and lymphocyte ransformation tests. J Investig Allergol Clin Immunol 2005; 15(4): 293–6PubMed Gex-Collet C, Helbling A, Pichler WJ. Multiple drug hypersensitivity: proof of multiple drug hypersensitivity by patch and lymphocyte ransformation tests. J Investig Allergol Clin Immunol 2005; 15(4): 293–6PubMed
120.
go back to reference Roepke S, Treudler R, Anghelescu I, et al. Valproic acid and hypersensitivity syndrome [letter]. Am J Psychiatry 2004 Mar; 161(3): 579PubMedCrossRef Roepke S, Treudler R, Anghelescu I, et al. Valproic acid and hypersensitivity syndrome [letter]. Am J Psychiatry 2004 Mar; 161(3): 579PubMedCrossRef
121.
go back to reference Neukomm CB, Yawalkar N, Helbling A, et al. T-cell reactions to drugs in distinct clinical manifestations of drug allergy. J Investig Allergol Clin Immunol 2001; 11(4): 275–84PubMed Neukomm CB, Yawalkar N, Helbling A, et al. T-cell reactions to drugs in distinct clinical manifestations of drug allergy. J Investig Allergol Clin Immunol 2001; 11(4): 275–84PubMed
122.
go back to reference Miranda-Romero A, Pérez-Oliva N, Aragoneses H, et al. Carbamazepine hypersensitivity syndrome mimicking mycosis fungoides. Cutis 2001 Jan; 67(1): 47–51PubMed Miranda-Romero A, Pérez-Oliva N, Aragoneses H, et al. Carbamazepine hypersensitivity syndrome mimicking mycosis fungoides. Cutis 2001 Jan; 67(1): 47–51PubMed
123.
go back to reference Hsiao CJ, Lee JY, Wong TW, et al. Extensive fixed drug eruption due to lamotrigine. Br J Dermatol 2001 Jun; 144(6): 1289–91PubMedCrossRef Hsiao CJ, Lee JY, Wong TW, et al. Extensive fixed drug eruption due to lamotrigine. Br J Dermatol 2001 Jun; 144(6): 1289–91PubMedCrossRef
124.
go back to reference Pasmans SG, Bruijnzeel-Koomen CA, van Reijsen FC. Skin reactions to carbamazepine. Allergy 1999 Jun; 54(6): 649–50PubMedCrossRef Pasmans SG, Bruijnzeel-Koomen CA, van Reijsen FC. Skin reactions to carbamazepine. Allergy 1999 Jun; 54(6): 649–50PubMedCrossRef
125.
go back to reference Galindo Bonilla PA, Romero Aguilera G, Feo Brito F, et al. Phenytoin hypersensitivity syndrome with positive patch test: a possible cross-reactivity with amitriptyline. J Investig Allergol Clin Immunol 1998 May–Jun; 8(3): 186–90PubMed Galindo Bonilla PA, Romero Aguilera G, Feo Brito F, et al. Phenytoin hypersensitivity syndrome with positive patch test: a possible cross-reactivity with amitriptyline. J Investig Allergol Clin Immunol 1998 May–Jun; 8(3): 186–90PubMed
126.
go back to reference Liao HT, Hung KL, Wang CF, et al. Patch testing in the detection of cutaneous reactions caused by carbamazepine. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1997 Sep–Oct; 38(5): 365–9PubMed Liao HT, Hung KL, Wang CF, et al. Patch testing in the detection of cutaneous reactions caused by carbamazepine. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1997 Sep–Oct; 38(5): 365–9PubMed
127.
go back to reference De Argila D, Angeles Gonzalo M, Rovira I. Carbamazepine-induced fixed drug eruption. Allergy 1997 Oct; 52(10): 1039PubMedCrossRef De Argila D, Angeles Gonzalo M, Rovira I. Carbamazepine-induced fixed drug eruption. Allergy 1997 Oct; 52(10): 1039PubMedCrossRef
128.
go back to reference Maquiera E, Yanez S, Fernandez L, et al. Mononu-cleosis-like illness as a manifestation of carbamazepine-induced anticonvulsant hypersensitivity syndrome. Allergol Immunopathol (Madr) 1996 Mar–Apr; 24(2): 87–8 Maquiera E, Yanez S, Fernandez L, et al. Mononu-cleosis-like illness as a manifestation of carbamazepine-induced anticonvulsant hypersensitivity syndrome. Allergol Immunopathol (Madr) 1996 Mar–Apr; 24(2): 87–8
129.
go back to reference De Vriese AS, Philippe J, Van Renterghem DM, et al. Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature. Medicine (Baltimore) 1995 May; 74(3): 144–51CrossRef De Vriese AS, Philippe J, Van Renterghem DM, et al. Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature. Medicine (Baltimore) 1995 May; 74(3): 144–51CrossRef
130.
go back to reference Corazza M, Mantovani L, Casetta I, et al. Exfoliative dermatitis caused by carbamazepine in a patient with isolated IgA deficiency. Contact Dermatitis 1995 Dec; 33(6): 447PubMedCrossRef Corazza M, Mantovani L, Casetta I, et al. Exfoliative dermatitis caused by carbamazepine in a patient with isolated IgA deficiency. Contact Dermatitis 1995 Dec; 33(6): 447PubMedCrossRef
131.
go back to reference Alanko K. Topical provocation of fixed drug eruption: a study of 30 patients. Contact Dermatitis 1994 Jul; 31(1): 25–7PubMedCrossRef Alanko K. Topical provocation of fixed drug eruption: a study of 30 patients. Contact Dermatitis 1994 Jul; 31(1): 25–7PubMedCrossRef
132.
go back to reference Rodriguez Mosquera M, Iglesias A, Saez A, et al. Patch test diagnosis of carbamazepine sensitivity? Contact Dermatitis 1991 Aug; 25(2): 137–8PubMedCrossRef Rodriguez Mosquera M, Iglesias A, Saez A, et al. Patch test diagnosis of carbamazepine sensitivity? Contact Dermatitis 1991 Aug; 25(2): 137–8PubMedCrossRef
133.
134.
go back to reference Camarasa JG. Patch test diagnosis of exfoliative dermatitis due to carbamazepine. Contact Dermatitis 1985 Jan; 12(1): 49PubMedCrossRef Camarasa JG. Patch test diagnosis of exfoliative dermatitis due to carbamazepine. Contact Dermatitis 1985 Jan; 12(1): 49PubMedCrossRef
135.
go back to reference Houwerzijl J, de Gast GC, Nater JP. Patch tests in drug eruptions. Contact Dermatitis 1975 Jun; 1(3): 180–1PubMedCrossRef Houwerzijl J, de Gast GC, Nater JP. Patch tests in drug eruptions. Contact Dermatitis 1975 Jun; 1(3): 180–1PubMedCrossRef
136.
go back to reference Calkin JM, Maibach HI. Delayed hypersensitivity drug reactions diagnosed by patch testing. Contact Dermatitis 1993; 29(5): 223–33PubMedCrossRef Calkin JM, Maibach HI. Delayed hypersensitivity drug reactions diagnosed by patch testing. Contact Dermatitis 1993; 29(5): 223–33PubMedCrossRef
137.
go back to reference Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007 Aug; 7(4): 317–23PubMedCrossRef Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007 Aug; 7(4): 317–23PubMedCrossRef
138.
go back to reference Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006 Apr; 16(4): 297–306PubMedCrossRef Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006 Apr; 16(4): 297–306PubMedCrossRef
139.
go back to reference Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. RegiSCAR Study Group. Pharmacogenet Genomics 2008 Feb; 18(2): 99–107PubMedCrossRef Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. RegiSCAR Study Group. Pharmacogenet Genomics 2008 Feb; 18(2): 99–107PubMedCrossRef
140.
go back to reference Alfirevic A, Mills T, Harrington P, et al. Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet Genomics 2006 Apr; 16(4): 287–96PubMedCrossRef Alfirevic A, Mills T, Harrington P, et al. Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet Genomics 2006 Apr; 16(4): 287–96PubMedCrossRef
141.
go back to reference Lonjou C, Thomas L, Borot N, et al., RegiSCAR Group. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006 Jul–Aug; 6(4): 265–8PubMed Lonjou C, Thomas L, Borot N, et al., RegiSCAR Group. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006 Jul–Aug; 6(4): 265–8PubMed
142.
go back to reference Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004 Apr 1; 428(6982): 486PubMedCrossRef Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004 Apr 1; 428(6982): 486PubMedCrossRef
143.
go back to reference Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005 Mar 15; 102(11): 4134–9PubMedCrossRef Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005 Mar 15; 102(11): 4134–9PubMedCrossRef
145.
go back to reference Hung SI, Chung WH, Chen YT. Genetica of severe drug hypersensitivity reactions in Han Chinese. In: Pichler WJ, editor. Drug hypersensitivity. Basel: Karger, 2007: 105–14CrossRef Hung SI, Chung WH, Chen YT. Genetica of severe drug hypersensitivity reactions in Han Chinese. In: Pichler WJ, editor. Drug hypersensitivity. Basel: Karger, 2007: 105–14CrossRef
Metadata
Title
Patch Testing for the Diagnosis of Anticonvulsant Hypersensitivity Syndrome
A Systematic Review
Authors
Abdelbaset A. Elzagallaai
Sandra R. Knowles
Michael J. Rieder
John R. Bend
Neil H. Shear
Dr Gideon Koren
Publication date
01-05-2009
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 5/2009
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200932050-00003

Other articles of this Issue 5/2009

Drug Safety 5/2009 Go to the issue